1. Home
  2. MESO vs IIPR Comparison

MESO vs IIPR Comparison

Compare MESO & IIPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • IIPR
  • Stock Information
  • Founded
  • MESO 2004
  • IIPR 2016
  • Country
  • MESO Australia
  • IIPR United States
  • Employees
  • MESO N/A
  • IIPR N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • IIPR Real Estate
  • Sector
  • MESO Health Care
  • IIPR Finance
  • Exchange
  • MESO Nasdaq
  • IIPR Nasdaq
  • Market Cap
  • MESO 1.4B
  • IIPR 1.5B
  • IPO Year
  • MESO N/A
  • IIPR 2016
  • Fundamental
  • Price
  • MESO $10.97
  • IIPR $54.58
  • Analyst Decision
  • MESO Buy
  • IIPR Hold
  • Analyst Count
  • MESO 4
  • IIPR 7
  • Target Price
  • MESO $18.00
  • IIPR $88.75
  • AVG Volume (30 Days)
  • MESO 156.4K
  • IIPR 256.6K
  • Earning Date
  • MESO 02-26-2025
  • IIPR 05-07-2025
  • Dividend Yield
  • MESO N/A
  • IIPR 13.90%
  • EPS Growth
  • MESO N/A
  • IIPR N/A
  • EPS
  • MESO N/A
  • IIPR 5.19
  • Revenue
  • MESO $5,670,000.00
  • IIPR $304,785,000.00
  • Revenue This Year
  • MESO $152.37
  • IIPR N/A
  • Revenue Next Year
  • MESO $336.12
  • IIPR $2.23
  • P/E Ratio
  • MESO N/A
  • IIPR $10.53
  • Revenue Growth
  • MESO N/A
  • IIPR N/A
  • 52 Week Low
  • MESO $5.78
  • IIPR $45.44
  • 52 Week High
  • MESO $22.00
  • IIPR $138.35
  • Technical
  • Relative Strength Index (RSI)
  • MESO 44.34
  • IIPR 48.50
  • Support Level
  • MESO $10.77
  • IIPR $52.76
  • Resistance Level
  • MESO $11.61
  • IIPR $57.09
  • Average True Range (ATR)
  • MESO 0.47
  • IIPR 1.76
  • MACD
  • MESO 0.09
  • IIPR 0.74
  • Stochastic Oscillator
  • MESO 27.68
  • IIPR 58.44

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About IIPR Innovative Industrial Properties Inc.

Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.

Share on Social Networks: